A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GAP
- 07 Oct 2019 Status changed from recruiting to completed.
- 15 Dec 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Feb 2014 New trial record